Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on HCA Healthcare (HCA) today and set a price target of $155.00. The company’s shares closed last Monday at $146.42, close to its 52-week high of $150.17.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 16.3% and a 70.3% success rate. Wiederhorn covers the Services sector, focusing on stocks such as The Ensign Group, Addus Homecare, and UnitedHealth.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HCA Healthcare with a $161.45 average price target, implying a 9.5% upside from current levels. In a report issued on January 13, Barclays also maintained a Buy rating on the stock with a $172.00 price target.
See today’s analyst top recommended stocks >>
HCA Healthcare’s market cap is currently $48.03B and has a P/E ratio of 14.17. The company has a Price to Book ratio of -13.51.
Based on the recent corporate insider activity of 123 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCA Healthcare, Inc. is a health care services company, which engages in operating hospitals, freestanding surgery centers and emergency rooms, and urgent care centers. It offers a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. The company was founded on November 22, 2010 and is headquartered in Nashville, TN.
